# EDGAR Filing Document

**Accession Number:** 0001708035
**File Stem:** 0001708035-26-000067
**Filing Date:** 2026-5
**Character Count:** 150058
**Document Hash:** 752ba4e408e9bb21769813cf08da9639
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001708035-26-000067.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001708035-26-000067

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 95

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ecovyst Inc.
- **CENTRAL INDEX KEY:** 0001708035
- **STANDARD INDUSTRIAL CLASSIFICATION:** CHEMICALS & ALLIED PRODUCTS [2800]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 813406833
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38221
- **FILM NUMBER:** 26942822

**BUSINESS ADDRESS:**
- **STREET 1:** 600 LEE ROAD, SUITE 200
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** 484-617-1200

**MAIL ADDRESS:**
- **STREET 1:** 600 LEE ROAD, SUITE 200
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PQ Group Holdings Inc.
- **DATE OF NAME CHANGE:** 20170531

?xml version='1.0' encoding='ASCII'? ecvt-20260331

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

---

| | |
|:---|:---|
| **(Mark One)** | **(Mark One)** |
| ☒ | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

**For the quarterly period ended March 31, 2026**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**Commission File Number: 001-38221** 

**Ecovyst Inc.**

---

| | |
|:---|:---|
| **Delaware** | **81-3406833** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |
| **600 Lee Road, Suite 200** |  |
| **Wayne, Pennsylvania** | **19087** |
| (Address of principal executive offices) | (Zip Code) |
| **(484)** | **617-1200** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |
| (Former address, if changed since last report) | (Former address, if changed since last report) |

---

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol** | **Name of each exchange on which registered** |
| Common stock, par value $0.01 per share | ECVT | New York Stock Exchange |

---

------

---

| | | | |
|:---|:---|:---|:---|
| Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ | Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ | Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ | Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ |
| Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ | Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ | Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ | Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐ |
| Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. | Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. | Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. | Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. |
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
| Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☒ | Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☒ | Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☒ | Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☒ |
| The number of shares of common stock outstanding as of April 29, 2026 was 109,453,484. | The number of shares of common stock outstanding as of April 29, 2026 was 109,453,484. | The number of shares of common stock outstanding as of April 29, 2026 was 109,453,484. | The number of shares of common stock outstanding as of April 29, 2026 was 109,453,484. |

---

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**Ecovyst Inc.**

**INDEX—FORM 10-Q**

**March 31, 2026**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| **<u>[PART I](#i15573aa9b05948f0b3c16e51a49a9821_10)</u>** | **<u>[FINANCIAL INFORMATION](#i15573aa9b05948f0b3c16e51a49a9821_10)</u>** | |
| <u>[Item 1.](#i15573aa9b05948f0b3c16e51a49a9821_13)</u> | <u>[Financial Statements (Unaudited)](#i15573aa9b05948f0b3c16e51a49a9821_13)</u> |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of](#i15573aa9b05948f0b3c16e51a49a9821_16)[Income](#i15573aa9b05948f0b3c16e51a49a9821_16)[(Loss)](#i15573aa9b05948f0b3c16e51a49a9821_16)</u> | <u>[4](#i15573aa9b05948f0b3c16e51a49a9821_16)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Comprehensive](#i15573aa9b05948f0b3c16e51a49a9821_19)[Income](#i15573aa9b05948f0b3c16e51a49a9821_19)[(Loss)](#i15573aa9b05948f0b3c16e51a49a9821_19)</u> | <u>[5](#i15573aa9b05948f0b3c16e51a49a9821_19)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Balance Sheets](#i15573aa9b05948f0b3c16e51a49a9821_22)</u> | <u>[6](#i15573aa9b05948f0b3c16e51a49a9821_22)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Stockholders' Equity](#i15573aa9b05948f0b3c16e51a49a9821_25)</u> | <u>[7](#i15573aa9b05948f0b3c16e51a49a9821_25)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows](#i15573aa9b05948f0b3c16e51a49a9821_28)</u> | <u>[8](#i15573aa9b05948f0b3c16e51a49a9821_28)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Condensed Consolidated Financial Statements](#i15573aa9b05948f0b3c16e51a49a9821_31)</u> | <u>[10](#i15573aa9b05948f0b3c16e51a49a9821_31)</u> |
| <u>[Item 2.](#i15573aa9b05948f0b3c16e51a49a9821_136)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i15573aa9b05948f0b3c16e51a49a9821_136)</u> | <u>[26](#i15573aa9b05948f0b3c16e51a49a9821_136)</u> |
| <u>[Item 3.](#i15573aa9b05948f0b3c16e51a49a9821_151)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i15573aa9b05948f0b3c16e51a49a9821_151)</u> | <u>[36](#i15573aa9b05948f0b3c16e51a49a9821_151)</u> |
| <u>[Item 4.](#i15573aa9b05948f0b3c16e51a49a9821_154)</u> | <u>[Controls and Procedures](#i15573aa9b05948f0b3c16e51a49a9821_154)</u> | <u>[36](#i15573aa9b05948f0b3c16e51a49a9821_154)</u> |
| **<u>[PART II](#i15573aa9b05948f0b3c16e51a49a9821_157)</u>** | **<u>[OTHER INFORMATION](#i15573aa9b05948f0b3c16e51a49a9821_157)</u>** |  |
| <u>[Item 1.](#i15573aa9b05948f0b3c16e51a49a9821_160)</u> | <u>[Legal Proceedings](#i15573aa9b05948f0b3c16e51a49a9821_160)</u> | <u>[37](#i15573aa9b05948f0b3c16e51a49a9821_160)</u> |
| <u>[Item 1A.](#i15573aa9b05948f0b3c16e51a49a9821_163)</u> | <u>[Risk Factors](#i15573aa9b05948f0b3c16e51a49a9821_163)</u> | <u>[37](#i15573aa9b05948f0b3c16e51a49a9821_163)</u> |
| <u>[Item 2.](#i15573aa9b05948f0b3c16e51a49a9821_166)</u> | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i15573aa9b05948f0b3c16e51a49a9821_166)</u> | <u>[37](#i15573aa9b05948f0b3c16e51a49a9821_166)</u> |
| <u>[Item 5.](#i15573aa9b05948f0b3c16e51a49a9821_169)</u> | <u>[Other Information](#i15573aa9b05948f0b3c16e51a49a9821_169)</u> | <u>[37](#i15573aa9b05948f0b3c16e51a49a9821_169)</u> |
| <u>[Item 6.](#i15573aa9b05948f0b3c16e51a49a9821_175)</u> | <u>[Exhibits](#i15573aa9b05948f0b3c16e51a49a9821_175)</u> | <u>[38](#i15573aa9b05948f0b3c16e51a49a9821_175)</u> |
|  | **<u>[SIGNATURES](#i15573aa9b05948f0b3c16e51a49a9821_178)</u>** | <u>[39](#i15573aa9b05948f0b3c16e51a49a9821_178)</u> |

---

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**PART I**—**FINANCIAL INFORMATION**

**ITEM 1. &nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL STATEMENTS (UNAUDITED)**

**ECOVYST INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)**

**(in thousands, except share and per share amounts)**

**(unaudited)** 

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | &nbsp;&nbsp;**2026** | &nbsp;&nbsp;**2025** |
| Sales | $214952 | $143109 |
| Cost of goods sold | 178538 | 124011 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 36414 | 19098 |
| Selling, general and administrative expenses | 19126 | 16500 |
| Other operating expense, net | 4751 | 3579 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income (loss) | 12537 | (981) |
| Interest expense, net | 3172 | 8353 |
| Debt modification and extinguishment costs |  | 960 |
| Other expense, net | 30 | 78 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) from continuing operations before income taxes | 9335 | (10372) |
| Provision (benefit) for income taxes | 3589 | (2238) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) from continuing operations | 5746 | (8134) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income from discontinued operations, net of tax | (1432) | 4537 |
| Net income (loss) | $4314 | $(3597) |
| Net income (loss) per share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic income (loss) per share - continuing operations | $0.05 | $(0.07) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted income (loss) per share - continuing operations | $0.05 | $(0.07) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic (loss) income per share - discontinued operations | $(0.01) | $0.04 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted (loss) income per share - discontinued operations | $(0.01) | $0.04 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic income (loss) per share | $0.04 | $(0.03) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted income (loss) per share | $0.04 | $(0.03) |
| Weighted average shares outstanding: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 110693992 | 117264124 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 111792774 | 117264124 |

---

See accompanying notes to condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

**(in thousands)** 

**(unaudited)** 

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | &nbsp;&nbsp;**2026** | &nbsp;&nbsp;**2025** |
| Net income (loss) | $4314 | $(3597) |
| Other comprehensive income, net of tax: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension and postretirement benefits | (104) | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net gain (loss) from hedging activities | 1018 | (4304) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation |  | 4531 |
| Total other comprehensive income | 914 | 226 |
| Comprehensive income (loss) | $5228 | $(3371) |

---

See accompanying notes to condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(in thousands, except share and per share amounts)** 

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| ASSETS |  |  |
| Cash and cash equivalents | $162552 | $197193 |
| Accounts receivable, net | 94102 | 85313 |
| Inventories, net | 32236 | 26803 |
| Derivative assets | 1785 | 1312 |
| Prepaid and other current assets | 13619 | 8736 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 304294 | 319357 |
| Property, plant and equipment, net | 477756 | 481159 |
| Goodwill | 326744 | 326744 |
| Other intangible assets, net | 56589 | 59288 |
| Right-of-use lease assets | 43180 | 37935 |
| Other long-term assets | 38054 | 36495 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1246617 | $1260978 |
| LIABILITIES |  |  |
| Accounts payable | $49744 | $48048 |
| Operating lease liabilities—current | 10260 | 9495 |
| Accrued liabilities | 67919 | 63272 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 127923 | 120815 |
| Long-term debt, excluding current portion | 392764 | 392581 |
| Deferred income taxes | 115884 | 113288 |
| Operating lease liabilities—noncurrent | 33085 | 28666 |
| Other long-term liabilities | 1776 | 2188 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 671432 | 657538 |
| Commitments and contingencies (Note 15) |  |  |
| EQUITY |  |  |
| Common stock ($0.01 par); authorized shares 450,000,000; issued shares 140,872,846 and 140,872,846 on March 31, 2026 and December 31, 2025, respectively; outstanding shares 109,450,306 and 111,805,102 on March 31, 2026 and December 31, 2025, respectively | 1409 | 1409 |
| Preferred stock ($0.01 par); authorized shares 50,000,000; no shares issued or outstanding on March 31, 2026 and December 31, 2025 |  |  |
| Additional paid-in capital | 1103372 | 1108525 |
| Accumulated deficit | (244320) | (248634) |
| Treasury stock, at cost; shares 31,422,540 and 29,067,744 on March 31, 2026 and December 31, 2025, respectively | (289461) | (261131) |
| Accumulated other comprehensive income | 4185 | 3271 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 575185 | 603440 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $1246617 | $1260978 |

---

See accompanying notes to condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(in thousands)**

**(unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common <br>stock** | **Additional <br>paid-in <br>capital** | **Accumulated deficit** | **Treasury <br>stock, at <br>cost** | **Accumulated <br>other <br>comprehensive <br>income** | **Total** |
| Balance, December 31, 2025 | $1409 | $1108525 | $(248634) | $(261131) | $3271 | $603440 |
| &nbsp;&nbsp;&nbsp;Net income |  |  | 4314 |  |  | 4314 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income |  |  |  |  | 914 | 914 |
| &nbsp;&nbsp;&nbsp;Repurchases of common shares |  |  |  | (35786) |  | (35786) |
| &nbsp;&nbsp;&nbsp;Excise tax on repurchases of common shares |  |  |  | (268) |  | (268) |
| &nbsp;&nbsp;&nbsp;Tax withholdings on equity award vesting |  |  |  | (1253) |  | (1253) |
| &nbsp;&nbsp;&nbsp;Stock compensation expense |  | 3658 |  |  |  | 3658 |
| &nbsp;&nbsp;&nbsp;Shares issued under equity incentive plan, net of forfeitures |  | (8811) |  | 8977 |  | 166 |
| Balance, March 31, 2026 | $1409 | $1103372 | $(244320) | $(289461) | $4185 | $575185 |
|  | **Common <br>stock** | **Additional <br>paid-in <br>capital** | **Accumulated deficit** | **Treasury <br>stock, at <br>cost** | **Accumulated <br>other <br>comprehensive <br>loss** | **Total** |
| Balance, December 31, 2024 | $1409 | $1106792 | $(177508) | $(222826) | $(7407) | $700460 |
| &nbsp;&nbsp;&nbsp;Net loss |  |  | (3597) |  |  | (3597) |
| &nbsp;&nbsp;&nbsp;Other comprehensive income |  |  |  |  | 226 | 226 |
| &nbsp;&nbsp;&nbsp;Tax withholdings on equity award vesting |  |  |  | (1477) |  | (1477) |
| &nbsp;&nbsp;&nbsp;Stock compensation expense |  | 3072 |  |  |  | 3072 |
| &nbsp;&nbsp;&nbsp;Shares issued under equity incentive plan, net of forfeitures |  | (9519) |  | 9519 |  |  |
| Balance, March 31, 2025 | $1409 | $1100345 | $(181105) | $(214784) | $(7181) | $698684 |

---

See accompanying notes to condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(in thousands)** 

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| Cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $4314 | $(3597) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss (income) from discontinued operations | 1432 | (4537) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) from continuing operations | 5746 | (8134) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 17791 | 15633 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization | 2699 | 2671 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred financing costs and original issue discount | 183 | 289 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income tax provision | 1929 | 1127 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss on asset disposals | 363 | 167 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock compensation | 3428 | 2519 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | (2534) | 851 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Working capital changes that provided (used) cash: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables | (8789) | (1518) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (5433) | 2318 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaids and other current assets | (5012) | (3916) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 1116 | (2929) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 8133 | (2340) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities, continuing operations | 19620 | 6738 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by operating activities, discontinued operations | (2682) | 3518 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 16938 | 10256 |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant and equipment | (14137) | (17094) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities, continuing operations | (14137) | (17094) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities, discontinued operations |  | (7159) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (14137) | (24253) |

---

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of long-term debt, net of original issue discount and financing fees |  | 870817 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of long-term debt |  | (873000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchases of common shares | (36339) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax withholdings on equity award vesting | (1253) | (1477) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | 150 | (15) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities, continuing operations | (37442) | (3675) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities, discontinued operations |  | (776) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (37442) | (4451) |
| Effect of exchange rate changes on cash and cash equivalents |  | (87) |
| Net change in cash and cash equivalents | (34641) | (18535) |
| Cash and cash equivalents at beginning of period | 197193 | 146013 |
| Cash and cash equivalents at end of period | $162552 | $127478 |
| Less: cash, cash equivalents, and restricted cash of discontinued operations |  | (11445) |
| Cash, cash equivalents and restricted cash at end of period of continuing operations | $162552 | $116033 |

---

For supplemental cash flow disclosures, see Note 19.

See accompanying notes to condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**1. Background and Basis of Presentation:**

***Description of Business***

Ecovyst Inc. and subsidiaries (the "Company" or "Ecovyst") is a leading provider of virgin and regenerated sulfuric acid products and services. The Company supports customers through its strategically located network of manufacturing facilities. The Company believes that its products and services contribute to improving the sustainability of the environment.

The Company has a uniquely positioned specialty business, Ecoservices, which provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides high quality and high strength virgin sulfuric acid for industrial and mining applications. Ecoservices also provides chemical waste handling and treatment services, as well as ex-situ catalyst activation services for the refining and petrochemical industry.

The Company's regeneration services product group typically experiences seasonal fluctuations as a result of higher demand for gasoline products in the summer months and lower demand in the winter months. These demand fluctuations result in higher sales and working capital requirements in the second and third quarters.

***Basis of Presentation***

The condensed consolidated financial statements included herein are unaudited. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States ("GAAP") have been condensed or omitted pursuant to such rules and regulations for interim reporting. In the opinion of management, all adjustments of a normal and recurring nature necessary to state fairly the financial position and results of operations have been included. The results of operations are not necessarily indicative of the expected results for the full year. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

On December 31, 2025, the Company completed the sale of its Advanced Materials & Catalysts business, which includes the Company's investment in affiliated companies, Zeolyst International and Zeolyst C.V. (collectively, the "Zeolyst Joint Venture"). The financial results of this business are presented as discontinued operations in the condensed consolidated financial statements. See Note 3 for more information on this transaction.

The notes to the condensed consolidated financial statements, unless otherwise indicated, are on a continuing operations basis.

**2. New Accounting Standards:**

***Accounting Standards Recently Adopted***

In July 2025, the Financial Accounting Standards Board ("FASB") issued guidance related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under *ASC 606*. This new guidance introduces a practical expedient for entities that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset. The new guidance is effective for fiscal years beginning after December 15, 2025 and interim periods within those fiscal years, with early adoption permitted. The Company has elected the practical expedient and applied the guidance as of January 1, 2026, with no material impact on the condensed consolidated financial statements and related disclosures.

***Accounting Standards Not Yet Adopted***

In November 2024, FASB issued guidance requiring public business entities ("PBEs") to disclose additional information on the nature of certain expenses presented in the income statement. The new guidance requires tabular disclosure of significant expense categories and qualitative descriptions for amounts not disaggregated from relevant expense categories. PBEs are required to define selling expenses and disaggregate the components. The new guidance is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The requirements must be applied prospectively; however, PBEs have the option to apply the guidance retrospectively. The disclosure will be implemented as required for the fiscal year ended December 31, 2027. The Company is currently evaluating the impact of this guidance.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**3. Divestiture:**

***Advanced Materials & Catalysts Divestiture***

On September 10, 2025, the Company entered into a definitive agreement to sell its Advanced Materials & Catalysts business, which includes the Zeolyst Joint Venture, to Technip Energies N.V. (the "Buyer") for a purchase price of $556,000 subject to certain adjustments including indebtedness, cash, working capital and transaction expenses, as set forth in the definitive agreement (the "Advanced Materials & Catalysts Sale"). The Company completed the Advanced Materials & Catalysts Sale effective on December 31, 2025. During the year ended December 31, 2025, the net cash proceeds to the Company from the sale were $568,427 after certain customary adjustments for indebtedness, working capital and cash at the closing of the transaction, which remains subject to customary post-closing adjustments. During the three months ended March 31, 2026, the Buyer provided a proposed closing statement, which the Company is currently reviewing in accordance with the terms of the definitive agreement. The calculation of the loss on sale in the Company's 2025 annual consolidated financial statements included an estimate of the potential adjustment to the closing purchase price. The Buyer's proposed closing statement indicates an estimated adjustment of up to $11,000 more than our estimate, which, if final, would affect the net loss on sale presented in discontinued operations and the final cash settlement. The Company intends to dispute any unsubstantiated adjustments accordingly.

The following table summarizes the results of discontinued operations related to the Advanced Materials & Catalysts business for the three months ended March 31, 2025:

---

| | |
|:---|:---|
| | **Three months ended<br>March 31, 2025** |
| Sales | $19088 |
| Cost of goods sold | 12571 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 6517 |
| Selling, general and administrative expenses | 4845 |
| Other operating expense, net | 1602 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income | 70 |
| Equity in net (income) from affiliated companies | (8916) |
| Interest expense, net <sup>(1)</sup>  | 2657 |
| Other expense, net | 105 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income from discontinued operations before income taxes | 6224 |
| Provision for income taxes | 1687 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income from discontinued operations, net of tax | $4537 |

---

<sup>(1)</sup> Upon the close of the Advanced Materials & Catalysts Sale and finalization of net cash proceeds, the Company was required to provide partial repayment under its Term Loan Credit Agreement dated as of January 30, 2025 (the "2025 Term Loan Facility"). As such, interest expense has been allocated to discontinued operations on the basis of the Company's partial repayment of $161,500 of the 2025 Term Loan Facility due June 12, 2031.

During the three months ended March 31, 2026, the Company incurred net loss from discontinued operations, net of tax of $1,432, primarily driven by transaction costs of $1,132.

Upon the close of the transaction, the Company entered into a Transition Services Agreement with the buyer pursuant to which the buyer is receiving certain services to provide for the orderly transition of various functions and processes after the closing of the transaction. The services under the Transition Services Agreement include information technology, accounting, tax, financial services, human resources and other administrative support services. These services are being provided at cost for a period of 10 months, with the ability to extend the initial term up to two extensions, the first of which shall not exceed two months and the second shall not exceed one month. The Company invoiced $767 pursuant to the Transition Services Agreement to the Buyer during the three months ended March 31, 2026.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

The disposal group included the Company's investment in an affiliated company, which was historically accounted for under the equity method. The following table provides summarized financial information of the combined investments in affiliated companies that were included within the divested business unit:

---

| | |
|:---|:---|
| | **Three months ended March 31, 2025** |
| Sales | $89530 |
| Gross profit | 28430 |
| Operating income | 18206 |
| Net income | 18651 |

---

Certain administrative services were provided to the affiliated company by the Company. The Company charged $576 for the three months ended March 31, 2025, which were included in selling, general and administrative expenses in the condensed consolidated statements of income (loss).

**4. Revenue from Contracts with Customers:**

***Disaggregated Revenue***

The Company's primary means of disaggregating revenue is by key end uses, which are described in the table below.

---

| | |
|:---|:---|
| **Key End Uses** | **Key Products** |
| Regeneration and treatment services | • Regenerated sulfuric acid |
| | • Hazardous waste treatment services |
| Industrial, mining & automotive | • Virgin sulfuric acid for mining |
| | • Virgin sulfuric acid derivatives for industrial production |
| | • Virgin sulfuric acid derivatives for nylon production |
| Other | • Catalyst activation |
| | • Aluminum sulfate solution |
| | • Ammonium bisulfite solution |

---

The following table disaggregates the Company's sales by key end uses, for the three months ended March 31, 2026 and 2025, respectively:

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| Regeneration and treatment services<sup>(1)</sup> | $93799 | $79247 |
| Industrial, mining & automotive | 112961 | 55879 |
| Other | 8192 | 7983 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total sales | $214952 | $143109 |

---

<sup>(1)</sup> As described in Note 1 to these condensed consolidated financial statements, the Company experiences seasonal sales fluctuations to customers in the regeneration services product group.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**5. Fair Value Measurements:**

Fair values are based on quoted market prices when available. When market prices are not available, fair values are generally estimated using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality. In instances where there is little or no market activity for the same or similar instruments, the Company estimates fair values using methods, models and assumptions that management believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of management estimation and judgment that becomes significant with increasingly complex instruments or pricing models. Where appropriate, adjustments are included to reflect the risk inherent in a particular methodology, model or input used.

The Company's financial assets and liabilities carried at fair value have been classified based upon a fair value hierarchy. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). The classification of an asset or a liability is based on the lowest level input that is significant to its measurement. For example, a Level 3 fair value measurement may include inputs that are both observable (Levels 1 and 2) and unobservable (Level 3). The levels of the fair value hierarchy are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1—Values are unadjusted quoted prices for identical assets and liabilities in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2—Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active, or other inputs that are observable or can be corroborated by market data for the term of the instrument. Such inputs include market interest rates and volatilities, spreads and yield curves.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3—Certain inputs are unobservable (supported by little or no market activity) and significant to the fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date.

***Fair value on a recurring basis***

The following tables present information about the Company's assets and liabilities that were measured at fair value on a recurring basis as of March 31, 2026 and December 31, 2025, and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31,<br>2026** | **Quoted Prices in <br>Active Markets <br>(Level 1)** | **Significant Other Observable Inputs (Level 2)** | **Significant <br>Unobservable Inputs <br>(Level 3)** |
| Derivative assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps (Note 12) | $2323 | $— | $2323 | $— |
| Derivative liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps (Note 12) | $381 | $— | $381 | $— |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31,<br>2025** | **Quoted Prices in <br>Active Markets <br>(Level 1)** | **Significant Other Observable Inputs (Level 2)** | **Significant <br>Unobservable Inputs <br>(Level 3)** |
| Derivative assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps (Note 12) | $1312 | $— | $1312 | $— |
| Derivative liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps (Note 12) | $1237 | $— | $1237 | $— |

---

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

*Derivative contracts*

Derivative assets and liabilities can be exchange-traded or traded over-the-counter ("OTC"). The Company generally values exchange-traded derivatives using models that calibrate to market transactions and eliminate timing differences between the closing price of the exchange-traded derivatives and their underlying instruments. OTC derivatives are valued using market transactions and other market evidence whenever possible, including market-based inputs to models, model calibration to market transactions, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. When models are used, the selection of a particular model to value an OTC derivative depends on the contractual terms of, and specific risks inherent in, the instrument as well as the availability of pricing information in the market. The Company generally uses similar models to value similar instruments. Valuation models require a variety of inputs, including contractual terms, market prices and rates, forward curves, measures of volatility, and correlations of such inputs. For OTC derivatives that trade in liquid markets, such as forward contracts, swaps and options, model inputs can generally be corroborated by observable market data by correlation or other means, and model selection does not involve significant management judgment.

As of March 31, 2026, the Company had interest rate caps that were fair valued using Level 2 inputs. In addition, the Company applies a credit valuation adjustment to reflect credit risk which is calculated based on credit default swaps. To the extent that the Company's net exposure under a specific master agreement is an asset, the Company utilizes the counterparty's default swap rate. If the net exposure under a specific master agreement is a liability, the Company utilizes a default swap rate comparable to Ecovyst. The credit valuation adjustment is added to the discounted fair value to reflect the exit price that a market participant would be willing to receive to assume the Company's liabilities or that a market participant would be willing to pay for the Company's assets.

**6. Stockholders' Equity:**

***Accumulated Other Comprehensive Income (Loss)***

The following tables present the tax effects of each component of other comprehensive income for the three months ended March 31, 2026 and 2025, respectively:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended March 31,** | **Three months ended March 31,** | **Three months ended March 31,** | **Three months ended March 31,** | **Three months ended March 31,** | **Three months ended March 31,** |
| | **2026** | **2026** | **2026** | **2025** | **2025** | **2025** |
| | **Pre-tax<br>amount** | **Tax benefit/<br>(expense)** | **After-tax amount** | **Pre-tax<br>amount** | **Tax benefit/<br>(expense)** | **After-tax amount** |
| Net loss from defined benefit and postretirement plans | $(138) | $34 | $(104) | $(1) | $— | $(1) |
| Net gain (loss) from hedging activities | 1357 | (339) | 1018 | (5738) | 1434 | (4304) |
| Foreign currency translation |  |  |  | 4531 |  | 4531 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income | $1219 | $(305) | $914 | $(1208) | $1434 | $226 |

---

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

The following tables present the changes in accumulated other comprehensive income (loss) ("AOCI"), net of tax, by component for the three months ended March 31, 2026 and 2025, respectively:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Defined benefit <br>and other <br>postretirement <br>plans** | **Net gain (loss) from hedging activities** | **Foreign <br>currency <br>translation** | **Total** |
| December 31, 2025 | $2450 | $821 | $— | $3271 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive (loss) income before reclassifications | (89) | 1298 |  | 1209 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from AOCI<sup>(1)</sup> | (15) | (280) |  | (295) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net current period other comprehensive (loss) income | (104) | 1018 |  | 914 |
| March 31, 2026 | $2346 | $1839 | $— | $4185 |
| December 31, 2024 | $1467 | $9902 | $(18776) | $(7407) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive (loss) income before reclassifications |  | (2699) | 4531 | 1832 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from AOCI<sup>(1)</sup> | (1) | (1605) |  | (1606) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net current period other comprehensive (loss) income | (1) | (4304) | 4531 | 226 |
| March 31, 2025 | $1466 | $5598 | $(14245) | $(7181) |

---

<sup>(1)</sup> See the following table for details about these reclassifications. Amounts in parentheses indicate debits.

The following table presents the reclassifications out of AOCI for the three months ended March 31, 2026 and 2025, respectively:

---

| | | | |
|:---|:---|:---|:---|
| **Details about AOCI Components** | **Amounts reclassified from AOCI**<sup>(1)</sup> | **Amounts reclassified from AOCI**<sup>(1)</sup> | **Affected line item where <br>income is presented** |
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** | |
|  | **2026** | **2025** |  |
| Amortization of defined benefit and other postretirement items: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss | $20 | $1 | Other expense, net<sup>(2)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax benefit | (5) |  | Provision (benefit) for income taxes |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net of tax | $15 | $1 |  |
| Gains and losses on cash flow hedges: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | $373 | $2140 | Interest expense |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax benefit | (93) | (535) | Provision (benefit) for income taxes |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net of tax | $280 | $1605 |  |
| Total reclassifications for the period, net of tax | $295 | $1606 |  |

---

<sup>(1)</sup> Amounts in parentheses indicate debits to profit/loss.

<sup>(2)</sup> These AOCI components are components of net periodic pension and other postretirement cost (see Note 14 to these condensed consolidated financial statements for additional details).

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

***Treasury Stock Repurchases***

*2022 Stock Repurchase Program*

On April 27, 2022, the Company's board of directors (the "Board") approved a stock repurchase program that authorized the Company to purchase up to $450,000 of the Company's common stock over the four-year period from the date of approval (the "Stock Repurchase Program"). On October 30, 2025, the Board amended the Stock Repurchase Program to remove the limitation that all repurchases must be made within the four-year period from the date of original approval. Under the plan, the Company is permitted to repurchase shares from time to time for cash in open market transactions or in privately negotiated transactions in accordance with applicable federal securities laws, with the Company determining the timing and the amount of any repurchases based on its evaluation of market conditions, share price and other factors.

During the three months ended March 31, 2026, the Company repurchased 3,226,461 shares on the open market at an average price of $11.07 per share, for a total of $35,721, excluding brokerage commissions and accrued excise tax. During the three months ended March 31, 2026, the Company accrued $268 of excise tax related to these repurchases, net of shares issued under the Company's equity incentive program (see Note 17 to these condensed consolidated financial statements). As of March 31, 2026, $146,486 was available for share repurchases under the program.

The Company did not repurchase any of its common stock pursuant to the stock repurchase program during the three months ended March 31, 2025.

*Tax Withholdings on Equity Award Vesting*

In connection with the vesting of restricted stock awards ("RSA" or "RSAs"), restricted stock units ("RSU" or "RSUs") and performance stock units ("PSU" or "PSUs"), shares of common stock may be delivered to the Company by employees to satisfy withholding tax obligations at the instruction of the employee award holders. These transactions, when they occur, are accounted for as stock repurchases by the Company, with the shares returned to treasury stock at a cost representing the payment by the Company of the tax obligations on behalf of the employees in lieu of shares for the vesting event. There were 121,608 and 189,446 shares delivered to the Company to cover tax payments for the three months ended March 31, 2026 and 2025, respectively, and the fair value of those shares withheld were $1,253 and $1,477 for the three months ended March 31, 2026 and 2025, respectively.

**7. Goodwill:**

The carrying amount of goodwill was $326,744 as of March 31, 2026 and December 31, 2025.

The Company completes its annual goodwill and indefinite-lived intangible assets impairment test during the fourth quarter of each year, or more frequently if triggering events indicate a possible impairment. The Company determined the fair value of its reporting unit using both a market approach and an income, or discounted cash flow, approach. As of October 1, 2025, the date of the Company's most recent quantitative assessments, the fair value of the Company's reporting unit and the fair value of the Company's indefinite-lived trade names and trademarks exceeded their respective carrying values.

During the three months ended March 31, 2026, the Company did not identify any events or circumstances that would more likely than not reduce the fair value of the Company's reporting unit below its carrying value.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**8. Acquisition:**

On May 6, 2025 (the "Closing Date"), the Company completed its acquisition of the sulfuric acid production assets of Cornerstone Chemical Company LLC ("Cornerstone") located in Waggaman, Louisiana. As part of an asset purchase agreement (the "Acquisition"), the Company paid $41,480 in cash, consisting of the $35,000 purchase price plus $6,480 of adjustments for working capital, pursuant to the agreement. The sulfuric acid production assets will be used to increase capacity of virgin sulfuric acid and regenerated sulfuric acid to current and future customers.

The following table sets forth the calculation and final allocation of the purchase price to the identifiable net assets acquired with respect to the Acquisition:

---

| | |
|:---|:---|
| | **Purchase<br>Price Allocation** |
| Cash paid | $41480 |
| Recognized amounts of identifiable assets acquired: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | $9991 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 3259 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment | 25000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other intangible assets | 2380 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term assets | 695 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of identifiable assets acquired | 41325 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 155 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets acquired | $41480 |

---

In accordance with the requirements of the purchase method of accounting for acquisitions, accounts receivable and inventories were recorded at fair market value. As of the Closing Date, the fair value of accounts receivable approximated historical cost. The gross contractual amount of accounts receivable at the Closing Date was $9,991, of which there was no amount deemed uncollectible. Fair value of inventory is defined as estimated selling prices less the sum of (a) costs of disposal and (b) a reasonable profit allowance for the selling effort of the acquiring entity.

Prior to the acquisition, the Company had a preexisting relationship with Cornerstone. The Company had a net payable for a sulfuric acid exchange balance that was settled in the amount of $450. As part of the acquisition terms, the payable was settled at cost, which was recorded separate from the business combination.

The valuation of intangibles assets acquired and the related weighted-average amortization period are as follows:

---

| | | |
|:---|:---|:---|
| | **Amount** | **Weighted-Average<br>Expected Useful Life<br>(in years)** |
| Intangible assets subject to amortization: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer relationships | $2380 | 15 |

---

Acquisition and integration costs were $264 and $806 for the three months ended March 31, 2026 and 2025, respectively, and are included in other operating expense, net in the Company's condensed consolidated statements of income (loss).

The Company entered into an agreement with Cornerstone to lease the land where the acquired assets are located for a 7-year term plus renewal options. Additionally, Cornerstone will charge the Company for site services and utilities for the location.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**9. Other Operating Expense, Net:**

A summary of other operating expense, net is as follows:

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| Amortization expense | $2158 | $2130 |
| Transaction and other related costs | 1237 | 822 |
| Restructuring, integration and business optimization costs | 795 | 137 |
| Net loss on asset disposals | 363 | 167 |
| Other, net | 198 | 323 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other operating expense, net | $4751 | $3579 |

---

**10. Inventories, Net:**

Inventories, net are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out ("FIFO") or average cost method. The components of inventories, net consist of the following:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Finished products and work in process | $24824 | $21781 |
| Raw materials | 7412 | 5022 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total inventories, net | $32236 | $26803 |

---

**11. Long-term Debt:**

The summary of long-term debt is as follows:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| 2025 Term Loan Facility | $397088 | $397088 |
| ABL Facility |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total debt | 397088 | 397088 |
| Original issue discount | (2776) | (2886) |
| Deferred financing costs | (1548) | (1621) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term debt, net of original issue discount and deferred financing costs | $392764 | $392581 |

---

***Term Loan Facility***

In January 2025, the Company amended its Term Loan Credit Agreement dated as of June 12, 2024 to, among other things, (a) reduce the interest rate applicable to all outstanding SOFR term loans to Term SOFR plus 2.00% per annum from a maximum of Term SOFR plus 2.25% per annum and (b) reduce the interest rate applicable to all outstanding base rate term loans to the alternate base rate plus 1.00% per annum from a maximum of the alternate base rate plus 1.25% per annum.

The Company evaluated the terms of the amendment in accordance with *ASC 470-50 Debt - Modification and Extinguishment* and determined that the amendment was a modification of debt. As a result, the Company recorded $960 of third-party financing costs within debt modification and extinguishment costs in the condensed consolidated statements of income (loss) for the three months ended March 31, 2025. No original issue discount was paid in relation to the amendment.

The interest rate on the 2025 Term Loan Facility was 5.67% as of March 31, 2026.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

***ABL Facility***

The borrowings under the senior secured asset-based lending revolving credit facility as amended April 10, 2025 ("ABL Facility") bear interest at a rate equal to an adjusted Term SOFR or the base rate plus a margin of between 1.25% to 1.75% or 0.25% to 0.75%, respectively. The interest rate on the ABL Facility was 7.00% as of March 31, 2026.

***Fair Value of Debt***

The fair value of a financial instrument is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. As of March 31, 2026 and December 31, 2025, the fair value of the Company's term loan facility was $396,591. The fair value is classified as Level 2 based upon the fair value hierarchy (see Note 5 to these condensed consolidated financial statements for further information on fair value measurements).

**12. Financial Instruments:**

The Company uses interest rate related derivative instruments to manage its exposure to changes in interest rates on its variable-rate debt instruments. The Company does not speculate using derivative instruments.

By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is an asset, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is a liability, the Company owes the counterparty and therefore, the Company is not exposed to the counterparty's credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with high quality counterparties. The derivative instruments entered into by the Company do not contain credit-risk-related contingent features.

Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with the Company's derivative instruments is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken.

*Use of Derivative Financial Instruments to Manage Interest Rate Risk*

The Company is exposed to fluctuations in interest rates on its senior secured credit facilities. Changes in interest rates will not affect the market value of such debt but will affect the Company's interest payments over the term of the loans. Likewise, an increase in interest rates could have a material impact on the Company's condensed consolidated statements of cash flows. The Company hedges the interest rate fluctuations on debt obligations through interest rate cap agreements. The Company records these agreements at fair value as assets or liabilities in the condensed consolidated balance sheets. As the derivatives are designated and qualify as cash flow hedges, the gains or losses on the interest rate cap agreements are recorded in stockholders' equity as a component of other comprehensive income, net of tax. Reclassifications of the gains and losses on the interest rate cap agreements into earnings are recorded as part of interest expense in the condensed consolidated statements of income (loss) as the Company makes its interest payments on the hedged portion of its senior secured credit facilities. Fair value is determined based on estimated amounts that would be received or paid to terminate the contracts at the reporting date based on quoted market prices.

The following table provides a summary of the Company's interest rate cap agreements:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Financial instrument** | **Number of instruments** | **In effect as of March 31, 2026** | **Current notional amount of instruments in effect** | **Annuitized premium of instruments in effect** | **Cap rate in effect for all agreements at March 31, 2026** |
| Interest rate caps | 3 | 2 | $625000 | $30698 | 1.00% |

---

The current notional amounts of the two interest rate cap agreements in effect at March 31, 2026 are $175,000 and $450,000. The Company entered into a $175,000 interest rate cap agreement to mitigate interest rate volatility from August 2024 to July 2026 and a $450,000 interest rate cap agreement to mitigate interest rate volatility from November 2025 to October 2026.

The Company also entered into a $200,000 forward starting interest rate cap agreement to mitigate interest volatility from August 2026 to July 2028.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

The fair values of derivative instruments held as of March 31, 2026 and December 31, 2025, respectively, are shown below:

---

| | | | |
|:---|:---|:---|:---|
| | **Balance sheet location** | **March 31,<br>2026** | **December 31,<br>2025** |
| *Derivative assets* |  |  |  |
| Derivatives designated as cash flow hedges: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Prepaid and other current assets | $810 | $446 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Other long-term assets | 538 |  |
|  |  | 1348 | 446 |
| Derivative not designated as hedging instrument: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Prepaid and other current assets | 975 | 866 |
| Total derivative assets |  | $2323 | $1312 |
| *Derivative liabilities* |  |  |  |
| Derivatives designated as cash flow hedges: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Accrued liabilities | $381 | $841 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Other long-term liabilities |  | 396 |
| Total derivative liabilities |  | $381 | $1237 |

---

The following tables show the effect of the Company's derivative instruments designated as cash flow hedges on AOCI and the condensed consolidated statements of income (loss) for the three months ended March 31, 2026 and 2025, respectively:

---

| | | |
|:---|:---|:---|
| | **Amount of gain (loss) recognized in OCI** | **Amount of gain (loss) recognized in OCI** |
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | $1730 | $(3598) |
|  | **Amount of loss reclassified from AOCI** | **Amount of loss reclassified from AOCI** |
|  | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
|  | **2026** | **2025** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | $(373) | $(2140) |
|  | **Amount of loss reclassified into income** | **Amount of loss reclassified into income** |
|  | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
|  | **2026** | **2025** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | $373 | $2140 |

---

The following table shows the amounts in the line items presented in the condensed consolidated statements of income (loss) in which the effects of derivatives designated as cash flow hedges are recorded for the three months ended March 31, 2026 and 2025, respectively:

---

| | | | |
|:---|:---|:---|:---|
| | | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| |<br>**Location and amount of gain (loss) recognized in income on cash flow hedging relationships** | **2026** | **2025** |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate caps | Interest expense, net | $(3172) | $(8353) |

---

The amount of net unrealized gains in AOCI related to the Company's cash flow hedges that is expected to be reclassified to the condensed consolidated statements of income (loss) over the next twelve months is $1,160 as of March 31, 2026.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**13. Income Taxes:**

The effective income tax rate for the three months ended March 31, 2026 was 38.4%, compared to 21.6% for the three months ended March 31, 2025. The Company's effective income tax rates for the three months ended March 31, 2026 and 2025, respectively, fluctuated primarily due to the increased discrete tax impact relative to pre-tax book income related to a stock compensation shortfall.

The difference between the U.S. federal statutory income tax rate and the Company's effective income tax rate for the three months ended March 31, 2026 was mainly due to state and local taxes, and a shortfall tax expense related to stock compensation.

The difference between the U.S. federal statutory income tax rate and the Company's effective income tax rate for the three months ended March 31, 2025 was mainly due to state and local taxes, and a shortfall tax expense related to stock compensation.

**14. Benefit Plans:**

The following table presents the components of net periodic (benefit) expense for the Company-sponsored defined benefit pension plan, which cover certain employees and retirees located in the U.S.:

*Defined Benefit Pension Plans*

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| Interest cost | $789 | $823 |
| Expected return on plan assets | (842) | (809) |
| Settlement gain | (19) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net periodic (benefit) expense | $(72) | $14 |

---

Net periodic (benefit) expense for the Company-sponsored postretirement benefit plan was immaterial for the three months ended March 31, 2026 and 2025. All components of net periodic (benefit) expense are presented within other expense, net in the Company's condensed consolidated statements of income (loss).

**15. Commitments and Contingent Liabilities:**

There is a risk of environmental impact in the Company's manufacturing operations. The Company's environmental policies and practices are designed to comply with existing laws and regulations and to minimize the possibility of significant environmental impact. The Company is also subject to various other lawsuits and claims with respect to matters such as governmental regulations, labor and other actions arising out of the normal course of business. All claims that are probable and reasonably estimable have been accrued for in the Company's condensed consolidated financial statements. When these matters are ultimately concluded and determined, the Company believes that there will be no material adverse effect on its condensed consolidated financial position, results of operations or liquidity.

**16. Segment Information:**

The segment information herein excludes the results of the divested Advanced Materials & Catalysts segment, which is reflected in discontinued operations as described in Note 3, for all periods presented.

The Company has one operating segment which represents one reportable segment under GAAP. The Company's single reportable segment, Ecoservices, derives its revenue through the sale of virgin and regenerated sulfuric acid products and services.

The Company's chief operating decision maker ("CODM") is its Chief Executive Officer. The Company's CODM evaluates the segment operating results for performance assessment and resource allocation purposes based upon entity-wide sales and expense information reported in the condensed consolidated statements of income (loss). The primary measure of segment profit (loss) is net income (loss) from continuing operations as reported in the condensed consolidated statements of income (loss). Significant segment expense categories evaluated by the CODM include cost of goods sold, selling, general and administrative expenses, and the other line items reported in the condensed consolidated statements of income (loss). As the Company has a single reportable segment, assets are reported in the condensed consolidated balance sheets and capital expenditures are reported in the condensed consolidated statements of cash flows.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

**17. Stock-Based Compensation:**

The Company has an equity incentive plan under which it grants common stock awards to employees, directors and affiliates of the Company. At March 31, 2026, 7,046,759 shares of common stock were available for issuance under the plan. The Company settles these awards through the issuance of treasury shares under its equity incentive plan. The Company has granted RSAs, RSUs and PSUs as part of its equity incentive compensation program.

***Modifications***

The cumulative Adjusted EBITDA goals for the outstanding PSUs with performance periods from January 1, 2024 through December 31, 2026, and January 1, 2025 through December 31, 2027 included anticipated contributions from the Advanced Materials & Catalysts business and ceased to provide meaningful metrics on which the Company's performance during the remainder of the performance periods could be assessed. During the three months ended March 31, 2026, the Compensation Committee of the Company's Board ("Compensation Committee") determined that the cumulative Adjusted EBITDA goals from January 1, 2026 onwards would be adjusted based on applying the original growth rates at threshold, target and maximum to the 2025 continuing operations Adjusted EBITDA. Actual performance will be similarly calculated following the conclusion of the three-year performance periods. No adjustments were made to the three-year relative total shareholder return ("TSR") goals. The modifications resulted in incremental stock-based compensation expense during three months ended March 31, 2026 which was not material.

***Restricted Stock Awards, Restricted Stock Units and Performance Stock Units***

*RSU*

During the three months ended March 31, 2026, the Company granted 624,737 RSUs under its equity incentive plan. Each RSU provides the recipient with the right to receive a share of common stock subject to graded vesting terms based on service, which for the awards granted during the three months ended March 31, 2026, generally requires approximately one year of service for members of the Company's Board and approximately three years of service for employees. The value of the RSUs granted during the three months ended March 31, 2026 was based on the average of the high and low trading prices of the Company's common stock on the NYSE on the preceding trading day, in accordance with the Company's policy for valuing such awards. Compensation expense related to the RSUs is recognized on a straight-line basis over the respective vesting period.

*PSU*

<u>2026 Grants</u>

During the three months ended March 31, 2026, the Company granted 351,870 PSUs (at target) under its equity incentive plan. The PSUs granted during the three months ended March 31, 2026 provide the recipients with the right to receive shares of common stock dependent on 50% of a Company-specific financial performance target and 50% on the relative increase in the TSR goal ("the Performance measures"). The Performance measures are measured independently of each other, but achievement of both metrics is measured on the same three-year performance period from January 1, 2026 through December 31, 2028 ("Performance period"). Depending on the Company's performance relative to the Performance measures, each PSU award recipient is eligible to receive a percentage of the target number of shares granted to the recipient, ranging from zero to 200%. The PSUs, to the extent earned, will vest on the date the Compensation Committee certifies the achievement of the Performance measures for the Performance period, which will occur subsequent to the end of the Performance period and after the Company files its annual consolidated financial statements for the year ending December 31, 2028.

Achievement of the Company-specific financial performance target is measured based on the actual three-year cumulative results across the Performance period. The TSR goal is based on the Company's actual TSR performance against companies in the S&P 1500 Specialty Chemicals Index over the Performance period. The TSR goal, which determines how much of the 50% of the PSUs granted during 2026 may be earned, is considered a market condition as opposed to a vesting condition. Because a market condition is not considered a vesting condition, it is reflected in the grant date fair value of the award and the associated compensation cost based on the fair value of the award is recognized over the Performance period, regardless of whether the Company actually achieves the market condition or the level of achievement, as long as service is provided by the recipient.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

The Company used a Monte Carlo simulation to estimate the $15.61 weighted average fair value of the awards granted, subject to the TSR goal during the three months ended March 31, 2026, with the following weighted average assumptions:

---

| | |
|:---|:---|
| Expected dividend yield | —% |
| Risk-free interest rate | 3.57% |
| Expected volatility | 40.00% |
| Expected term (in years) | 2.90 |

---

<u>2023 Grants</u>

In March 2026, the Compensation Committee certified the achievement of the performance metrics for the three-year period ended December 31, 2025, related to the PSUs granted during the year ended December 31, 2023. The PSUs granted during the year ended December 31, 2023 provide the recipients with the right to receive shares of common stock dependent on the achievement of a TSR goal and are generally subject to the provision of service through the vesting date of the award. The TSR goal was based on the Company's actual TSR percentage increase over the performance period. The awards vested during the three months ended March 31, 2026 with no percentage of the TSR goal earned.

*Award Activity*

The following table summarizes the activity for the Company's RSUs and PSUs for the three months ended March 31, 2026:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Restricted Stock Units** | **Restricted Stock Units** | **Performance Stock Units** | **Performance Stock Units** | **Performance Stock Units** |
| | **Number of <br>units** | **Weighted average grant date fair value (per share)** | **Number of <br>units** | | **Weighted average grant date fair value (per share)** |
| Nonvested as of December 31, 2025 | 1464131 | $8.45 | 1491514 | (1) | $10.86 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 624737 | $10.44 | 351870 |  | $12.96 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested | (941817) | $8.64 |  |  | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (14284) | $9.32 | (596308) |  | $12.49 |
| Nonvested as of March 31, 2026 | 1132767 | $9.38 | 1247076 | (1) | $10.67 |

---

<sup>(1)</sup> Based on target.

During the three months ended March 31, 2026, the Company did not grant any RSAs. Cash proceeds received by the Company from the exercise of stock options were not material for the three months ended March 31, 2026.

***Stock-Based Compensation Expense***

For the three months ended March 31, 2026 and 2025, stock-based compensation expense for the Company included in continuing operations was $3,428 and $2,519, respectively. The associated income tax benefit based on the applicable statutory rate recognized in the condensed consolidated statements of income (loss) for the three months ended March 31, 2026 and 2025 was $937 and $632, respectively.

As of March 31, 2026, unrecognized compensation cost of $9,583 for RSUs and $7,718 for PSUs are considered probable of vesting and the weighted-average period over which these costs are expected to be recognized at March 31, 2026 was 1.89 years for the RSUs and 2.33 years for the PSUs.

**18. Earnings per Share:**

Basic earnings per share is calculated as income available to common stockholders, divided by the weighted average number of common shares outstanding during the period. The weighted average number of common shares outstanding during the period for the computation of basic earnings per share excludes RSAs that have legally been issued but are nonvested during the period, as the sale of these shares is prohibited pending satisfaction of certain vesting conditions by the award recipients in order to earn the rights to the shares.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

Diluted earnings per share is calculated as income available to common stockholders, divided by the weighted average number of common and potential common shares outstanding during the period, if dilutive. Potential common shares reflect (1) unvested RSAs and RSUs with service vesting conditions, (2) PSUs with vesting conditions considered probable of achievement and (3) options to purchase common stock, all of which have been included in the diluted earnings per share calculation using the treasury stock method.

The reconciliation from basic to diluted weighted average shares outstanding is as follows:

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| Weighted average shares outstanding – Basic | 110693992 | 117264124 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dilutive effect of unvested common shares and RSUs with service conditions, PSUs considered probable of vesting and assumed stock option exercises and conversions | 1098782 |  |
| Weighted average shares outstanding – Diluted | 111792774 | 117264124 |

---

We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is income from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories.

The Company reported a net loss from continuing operations for the three months ended March 31, 2025, and therefore excluded the dilutive effect of 295,438 shares, which consisted of unvested common shares, RSUs with service conditions, PSUs considered probable of vesting and assumed stock option exercises and conversions from the computation of weighted average diluted shares outstanding.

Basic and diluted income per share are calculated as follows:

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| **Numerator:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) from continuing operations | $5746 | $(8134) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income from discontinued operations, net of tax | (1432) | 4537 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $4314 | $(3597) |
| **Denominator:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted average shares outstanding – Basic | 110693992 | 117264124 |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted average shares outstanding – Diluted | 111792774 | 117264124 |
| **Net income (loss) per share:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic income (loss) per share - continuing operations | $0.05 | $(0.07) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted income (loss) per share - continuing operations | $0.05 | $(0.07) |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic (loss) income per share - discontinued operations | $(0.01) | $0.04 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted (loss) income per share - discontinued operations | $(0.01) | $0.04 |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic income (loss) per share | $0.04 | $(0.03) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted income (loss) per share | $0.04 | $(0.03) |

---

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ECOVYST INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts)**

**(unaudited)**

The table below presents the details of the Company's weighted average equity-based awards outstanding during each respective period that were excluded from the calculation of diluted earnings per share:

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| Anti-dilutive RSUs and PSUs | 222,852 | 1,365,654 |
| Anti-dilutive stock options | 367,100 | 367,100 |

---

Certain stock options to purchase shares of common stock were excluded from the computation of diluted earnings per share for the respective periods because the options' exercise price was greater than the average market price of the common shares. These stock options and anti-dilutive awards are not included in the dilution calculation, as their inclusion would have the effect of increasing diluted income per share.

**19. Supplemental Cash Flow Information:**

The following table presents supplemental cash flow information for the Company, which includes activity from both continuing and discontinued operations, except for operating leases which is continuing operations only:

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| Cash paid during the period for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes, net of refunds | $(129) | $2724 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest<sup>(1)</sup> | 4884 | 12301 |
| Non-cash investing activity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures acquired on account but unpaid as of the period end | 817 | 1430 |
| Non-cash financing activity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued excise tax on share repurchases (Note 6) | 268 |  |
| Right-of-use assets obtained in exchange for new lease liabilities (non-cash): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating leases | 7968 | 2607 |

---

<sup>(1)</sup> Cash paid for interest is shown net of capitalized interest and includes the cash received or paid on the Company's interest rate cap agreements designated as cash flow hedges for the periods presented (see Note 12 to these condensed consolidated financial statements for details).

**20. Subsequent Events:**

On May 1, 2026, the Company announced it signed a definitive agreement to acquire the Calabrian sulfur dioxide and sulfur derivatives business ("Calabrian") from INEOS Enterprises for a purchase price of $190,000 subject to customary closing conditions. The acquisition is expected to be financed through a combination of cash on hand and proceeds of new debt financing. Following closing, the acquisition is expected to expand the Company's existing product and service offering through further expansion into the sulfur dioxide, sodium bisulfite, sodium thiosulfate and sodium metabisulfite product groups. The Company expects the acquisition to close in the second quarter of 2026.

The Company has evaluated subsequent events since the balance sheet date and determined that there are no additional items to disclose.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ITEM 2. &nbsp;&nbsp;&nbsp;&nbsp;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.**

*Unless the context requires otherwise, references in this report to "Ecovyst," "the Company," "we," "us" or "our" refer to Ecovyst Inc. and its consolidated subsidiaries.*

**Forward-looking Statements**

*This periodic report on Form 10-Q ("Form 10-Q") includes "forward-looking statements" that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should" and similar expressions are intended to identify these forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Examples of forward-looking statements include, but are not limited to, statements we make regarding demand trends, economic effects on our operations and financial results and our liquidity, potential strategic acquisitions or divestitures, potential increased borrowing under our credit facilities, and our belief that our current level of operations, cash and cash equivalents, cash flow from operations and borrowings under our credit facilities and other lines of credit will provide us adequate cash to fund working capital requirements, capital expenditure projects, debt service requirements and other requirements for our business for at least the next twelve months.*

*These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.*

*Some of the key factors that could cause actual results to differ from our expectations include the following risks related to our business:*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we are exposed to general business risks;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we are affected by general economic conditions and economic downturns;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our operations require us to comply with regulations of the U.S. government as well as the state and local governments where we operate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• alternative technology may reduce or eliminate the need for certain of our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our substantial level of indebtedness could adversely affect our financial condition;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• if we are unable to manage the current and future inflationary environment and to pass on increases in raw material prices, including natural gas, or labor costs to our customers or to retain or replace our key suppliers, our results of operations and cash flows may be negatively affected;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we face substantial competition in the industries in which we operate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we are subject to the risk of loss resulting from non-payment or non-performance by our customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we rely on a limited number of customers for a meaningful portion of our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• multi-year customer contracts are subject to potential early termination and such contracts may not be renewed at the end of their respective terms;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our quarterly results of operations are subject to fluctuations because demand for some of our products is seasonal;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our growth projects may result in significant expenditures before generating revenues, if any, which may materially and adversely affect our ability to implement our business strategy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may be liable to damages based on product liability claims brought against us or our customers for costs associated with recalls of our or our customers' products;

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we are subject to extensive environmental, health and safety regulations and face various risks associated with potential non-compliance or releases of hazardous materials;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• existing and proposed regulations to address climate change by limiting greenhouse gas emissions may cause us to incur significant additional operating and capital expenses and may impact our business and results of operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other governmental legislation and regulation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• production and distribution of our products could be disrupted for a variety of reasons, including as a result of supply chain constraints, and such disruptions could expose us to significant losses or liabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the insurance that we maintain may not fully cover all potential exposures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we could be subject to damages based on claims brought against us by our customers or lose customers as a result of the failure of our products to meet certain quality specifications;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our failure to protect our intellectual property and infringement on the intellectual property rights of third parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• disruption, failure or cyber security breaches affecting or targeting computers and infrastructure used by us or our business partners may adversely impact our business and operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• significant trade developments, including tariffs, could have an adverse effect on us or our customers; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other factors set forth in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 (the "Annual Report on Form 10-K").

*The forward-looking statements included herein are made only as of the date hereof. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Form 10-Q to conform these statements to actual results or to changes in our expectations.*

**Overview** 

We are a leading provider of virgin sulfuric acid and regenerated sulfuric acid products and services. We believe that our Ecoservices business contributes to improving the sustainability of the environment.

We are a leading provider of sulfuric acid recycling to the North American refining industry for the production of alkylate, an essential gasoline component for lowering vapor pressure and increasing octane to meet stringent gasoline specifications and fuel efficiency standards. We are also a leading North American producer of high quality and high strength virgin sulfuric acid for industrial and mining applications. We also provide chemical waste handling and treatment services, as well as ex-situ catalyst activation services for the refining and petrochemical industry.

On December 31, 2025, the Company completed the sale of its Advanced Materials & Catalysts business. The results of operations, financial condition, and cash flows for the Advanced Materials & Catalysts are presented herein as discontinued operations. Except where noted, any tables, percentages or metrics included within this filing exclude the results of our Advanced Materials & Catalysts business. Refer to Note 3 to our condensed consolidated financial statements for additional information.

*Stock Repurchase Program*

On April 27, 2022, our Board of Directors (the "Board") approved a stock repurchase program that authorized the Company to purchase up to $450.0 million of the Company's common stock over the four-year period from the date of approval (the "Stock Repurchase Program"). On October 30, 2025, the Board amended the Stock Repurchase Program to remove the limitation that all repurchases must be made within the four-year period from the date of original approval. For the three months ended March 31, 2026, the Company repurchased 3,226,461 shares on the open market at an average price of $11.07 per share, for a total of $35.7 million excluding brokerage commissions and accrued excise tax. As of March 31, 2026, $146.5 million was available for share repurchases under the program.

The Company did not repurchase any of its common stock pursuant to the stock repurchase program during the three months ended March 31, 2025.

For possible future repurchases, the actual timing, number, and nature of shares repurchased will depend on a variety of factors, including stock price, trading volume, and general business and market conditions and may be conducted through negotiated

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

transactions, open market repurchases or other means, including through Rule 10b-18 and 10b5-1 trading plans or accelerated share repurchases.

**Key Performance Indicators**

***Adjusted EBITDA, Adjusted Net Income and Net Debt***

Adjusted EBITDA, Adjusted Net Income and Net Debt are financial measures that are not prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and that we use to evaluate our operating performance, for business planning purposes and to measure our performance relative to that of our competitors. Adjusted EBITDA, Adjusted Net Income, and Net Debt are presented as key performance indicators as we believe these financial measures will enhance a prospective investor's understanding of our results of operations and financial condition. EBITDA consists of net income (loss) from continuing operations before interest, taxes, depreciation and amortization. Adjusted EBITDA consists of EBITDA adjusted for (i) non-operating income or expense, and (ii) the impact of certain non-cash, nonrecurring or other items included in net income (loss) from continuing operations and EBITDA that we do not consider indicative of our ongoing operating performance. Adjusted Net Income consists of net income (loss) from continuing operations adjusted for (i) non-operating income or expense and (ii) the impact of certain non-cash, nonrecurring or other items included in net income (loss) from continuing operations that we do not consider indicative of our ongoing operating performance. Net Debt consists of total debt less cash and cash equivalents. We believe that these non-GAAP financial measures provide investors with useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

You should not consider Adjusted EBITDA, Adjusted Net Income, or Net Debt in isolation or as alternatives to the presentation of our financial results in accordance with GAAP. The presentation of Adjusted EBITDA, Adjusted Net Income and Net Debt financial measures may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures. In evaluating Adjusted EBITDA and Adjusted Net Income, you should be aware that we are likely to incur expenses similar to those eliminated in this presentation in the future and that certain of these items could be considered recurring in nature. Our presentation of Adjusted EBITDA and Adjusted Net Income should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. Reconciliations of Adjusted EBITDA, Adjusted Net Income to GAAP net income (loss) from continuing operations and Net Debt to GAAP total debt are included in this "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations" for each of the respective periods.

**Key Factors and Trends Affecting Operating Results and Financial Condition**

***Sales***

Sales are made on both a purchase order basis and pursuant to long-term contracts. We continued to benefit from positive demand trends for our products and services in the majority of end uses we serve. Strong demand for refined products continued to support high refinery utilization rates, while more stringent gasoline standards and growing demand for premium gasoline to power higher-compression and turbo-charged engines continued to drive demand for alkylate and for our regeneration services product group. In addition, demand for virgin sulfuric acid across a wide range of industrial applications, including mining, remained favorable.

***Cost of Goods Sold***

Cost of goods sold consists of variable product costs, fixed manufacturing expenses, depreciation expense and freight expenses. Variable product costs include all raw materials and energy costs that are directly related to the manufacturing process. Fixed manufacturing expenses include all plant employment costs, manufacturing overhead and periodic maintenance costs.

The primary raw materials include spent sulfuric acid, sulfur, acids, bases (including sodium hydroxide, or "caustic soda") and certain metals. Spent sulfuric acid for our regeneration services product group is supplied by customers as part of their contracts.

Most of our contracts feature take-or-pay volume protection and/or quarterly price adjustments for commodity inputs, labor, the Chemical Engineering Index (U.S. chemical plant construction cost index) and natural gas. About 90% of our sales for the year ended December 31, 2025 were under contracts featuring quarterly price adjustments. The price adjustments generally reflect actual costs for producing sulfuric acid and tend to protect us from volatility in labor, fixed costs and raw material pricing. The take-or-pay volume protection allows us to cover fixed costs through intermittent, temporary production issues at customer refineries.

While natural gas is not a direct feedstock for any product, natural gas powered machinery and equipment are used to heat raw materials and create the chemical reactions necessary to produce end-products. We maintain multiple suppliers wherever possible and structure our customer contracts when possible to allow for the pass-through of raw material, labor and natural gas costs.

***Seasonality***

Our regeneration services product group typically experiences seasonal fluctuations as a result of higher demand for gasoline products in the summer months and lower demand in the winter months as well as fluctuations associated with customer turnarounds. These demand fluctuations generally result in higher sales and working capital requirements in the second and third quarters.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**Results of Operations**

***Three Months Ended March 31, 2026 Compared to the Three Months Ended March 31, 2025***

***Highlights***

The following is a summary of our financial performance for the three months ended March 31, 2026 compared to the three months ended March 31, 2025.

*Sales*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* Sales increased $71.9 million to $215.0 million. The increase in sales primarily reflects higher average selling prices from the pass-through effect of higher sulfur costs, favorable contractual pricing for regenerated sulfuric acid and higher sales volume of virgin and regenerated sulfuric acid, including the contribution from the acquired Waggaman, Louisiana location.

*Gross Profit*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross profit increased $17.3 million to $36.4 million. The increase in gross profit was primarily due to higher sales volume and higher average selling prices, partially offset by higher manufacturing costs.

*Operating Income (Loss)*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating income (loss) increased by $13.5 million to $12.5 million. The increase in operating income (loss) was due to a increase in gross profit, partially offset by higher selling, general and administrative expenses.

The following is our unaudited condensed consolidated statements of income (loss) and a summary of financial results for the three months ended March 31, 2026 and 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** | **Change** |
| | **2026** | **2025** | $**%** |
| | **(in millions, except percentages)** | **(in millions, except percentages)** | **(in millions, except percentages)** |
| Sales | $215 | $143.1 | 50.2% |
| Cost of goods sold | 178.6 | 124.0 | 44.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 36.4 | 19.1 | 90.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit margin | *16.9 %* | *13.3 %* |  |
| Selling, general and administrative expenses | 19.1 | 16.5 | 15.8% |
| Other operating expense, net | 4.8 | 3.6 | 33.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income (loss) | 12.5 | (1.0) | 1350.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income (loss) margin | *5.8 %* | *(0.7) %* |  |
| Interest expense, net | 3.2 | 8.3 | (61.4)% |
| Debt modification and extinguishment costs |  | 1.0 | (100.0)% |
| Other expense, net |  | 0.1 | (100.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) before income taxes | 9.3 | (10.4) | 189.4% |
| Provision (benefit) for income taxes | 3.6 | (2.3) | (256.5)% |
| Effective tax rate | *38.4 %* | *21.6 %* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) from continuing operations | 5.7 | (8.1) | 170.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income from discontinued operations, net of tax | (1.4) | 4.5 | (131.1)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $4.3 | $(3.6) | 219.4% |

---

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

***Sales***

Sales for the three months ended March 31, 2026 were $215.0 million, an increase of $71.9 million, or 50.2%, compared to sales of $143.1 million for the three months ended March 31, 2025. The increase in sales reflects higher average selling prices of $39.7 million, including the pass-through effect of higher sulfur costs of approximately $33 million, and higher sales volume of $32.2 million.

Average selling prices were higher primarily due to the pass-through effect of higher sulfur costs, higher virgin sulfuric acid pricing and favorable contract pricing for regenerated sulfuric acid. Sales volume increase was a result of the contribution of sales volume from the Waggaman, Louisiana location, higher virgin sulfuric acid demand and higher regeneration services driven by less customer down-time compared to the prior year.

***Gross Profit***

Gross profit for the three months ended March 31, 2026 was $36.4 million, an increase of $17.3 million, or 90.6%, compared to $19.1 million for the three months ended March 31, 2025. The increase in gross profit was primarily driven by higher sales volume of $14.6 million and higher average selling prices of $6.7 million, exclusive of the approximately $33 million of higher sulfur costs, partially offset by higher manufacturing costs of $4.0 million, exclusive of the pass-through of sulfur costs. The cost of sulfur is generally passed-through to customers at the same rate as incurred resulting in no net impact to gross profit.

Higher manufacturing costs were driven by additional fixed costs from the Waggaman, Louisiana location, higher total turnaround costs of approximately $2 million, general inflation and higher transportation costs.

***Selling, General and Administrative Expenses***

Selling, general and administrative expenses for the three months ended March 31, 2026 were $19.1 million, an increase of $2.6 million, compared to $16.5 million for the three months ended March 31, 2025. The increase in selling, general and administrative expenses was mainly driven by an increase in stock compensation of $0.9 million, other compensation-related expenses of $1.2 million and other expenses of $0.5 million.

***Other Operating Expense, Net***

Other operating expense, net for the three months ended March 31, 2026 was $4.8 million, an increase of $1.2 million, compared to $3.6 million for the three months ended March 31, 2025. The increase in other operating expense, net was mainly driven by an increase in transaction costs of $0.4 million and an increase in other costs of $0.8 million primarily related to integration, restructuring and legal charges.

***Interest Expense, Net***

Interest expense, net for the three months ended March 31, 2026 was $3.2 million, a decrease of $5.1 million, as compared to $8.3 million for the three months ended March 31, 2025. The decrease in interest expense, net was primarily due to the year over year lower outstanding debt during the three months ended March 31, 2026, as compared to the three months ended March 31, 2025.

***Debt Modification and Extinguishment Costs***

There were no debt modification and extinguishment costs for the three months ended March 31, 2026, compared to $1.0 million for the three months ended March 31, 2025.

On January 30, 2025, we amended our existing senior secured term loan facility to reduce the applicable interest rates. We evaluated the terms of the amendment in accordance with *ASC 470-50 Debt - Modification and Extinguishment* and determined that the amendment was a modification of debt. As a result, we recorded $1.0 million of third-party financing fees within debt modification and extinguishment costs in the condensed consolidated statements of income (loss) during the three months ended March 31, 2025.

***Other Expense, Net***

There was no other expense, net for the three months ended March 31, 2026, compared to $0.1 million of other expense, net for the three months ended March 31, 2025.

***Provision (Benefit) For Income Taxes***

The provision for income taxes for the three months ended March 31, 2026 was $3.6 million, compared to a benefit for income taxes of $2.3 million for the three months ended March 31, 2025. The effective income tax rate for the three months ended March 31, 2026 was 38.4%, compared to 21.6% for the three months ended March 31, 2025.

Our effective income tax rate for the three months ended March 31, 2026 and 2025, respectively, fluctuated primarily due to the increased discrete tax impact relative to pre-tax book income related to a stock compensation shortfall.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

The difference between the U.S. federal statutory income tax rate and our effective income tax rate for the three months ended March 31, 2026 was mainly due to state and local taxes and a shortfall tax expense related to stock compensation impacting the effective income tax rate by 13%.

***Net Income (Loss) From Continuing Operations***

For the foregoing reasons, net income from continuing operations was $5.7 million for the three months ended March 31, 2026, compared to net loss from continuing operations of $8.1 million for the three months ended March 31, 2025.

***Adjusted EBITDA***

Adjusted EBITDA for the three months ended March 31, 2026 was $39.8 million, an increase of $18.5 million, or 86.9%, compared to $21.3 million for the three months ended March 31, 2025.

The increase in Adjusted EBITDA was driven by higher sales volume of virgin and regenerated sulfuric acid driven by higher demand, less customer down-time, and contribution from the Waggaman, Louisiana location. In addition, higher virgin sulfuric acid pricing and favorable contractual pricing for regenerated sulfuric acid contributed to the increase. This was partially offset by higher manufacturing costs driven by higher turnaround costs, along with general inflation and higher transportation costs.

A reconciliation of net income (loss) from continuing operations to Adjusted EBITDA is as follows:

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| | **(in millions)** | **(in millions)** |
| **Reconciliation of net income (loss) from continuing operations to Adjusted EBITDA** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) from continuing operations | $5.7 | $(8.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision (benefit) for income taxes | 3.6 | (2.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 3.2 | 8.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 20.5 | 18.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EBITDA | 33.0 | 16.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt modification and extinguishment costs |  | 1.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss on asset disposals<sup>(a)</sup> | 0.4 | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transaction and other related costs<sup>(b)</sup> | 1.2 | 0.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 3.4 | 2.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring, integration and business optimization expenses<sup>(c)</sup> | 0.8 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other<sup>(d)</sup> | 1.0 | 0.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA<sup>(1)</sup> | $39.8 | $21.3 |

---

<sup>(a)</sup>When asset disposals occur, we remove the impact of net gain/loss of the disposed asset because such impact primarily reflects the non-cash write-off of long-lived assets no longer in use.

<sup>(b)</sup>Relates to certain transaction costs, including debt financing, due diligence and other costs related to transactions that are completed, pending or abandoned, that we believe are not representative of our ongoing business operations.

<sup>(c)</sup>Includes the impact of restructuring, integration and business optimization expenses, which are incremental costs that are not representative of our ongoing business operations.

<sup>(d)</sup>Other consists of adjustments for items that are not core to our ongoing business operations. These adjustments include environmental remediation and other legal costs, expenses for capital and franchise taxes, and defined benefit pension and postretirement plan (benefits) costs, for which our obligations are under plans that are frozen. Included in this line-item are rounding discrepancies that may arise from rounding from dollars (in thousands) to dollars (in millions).

<sup>(1)</sup> We define Adjusted EBITDA as EBITDA adjusted for certain items as noted in the reconciliation above. Adjusted EBITDA does not represent cash flow for periods presented and should not be considered as an alternative to net income (loss) from continuing operations as an indicator of our operating performance or as an alternative to cash flows as a source of liquidity. Adjusted EBITDA may not be comparable with EBITDA or Adjusted EBITDA as defined by other companies.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

***Adjusted Net Income***

Summarized Adjusted Net Income information is shown below in the following table:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended March 31,** | **Three months ended March 31,** | **Three months ended March 31,** | **Three months ended March 31,** | **Three months ended March 31,** | **Three months ended March 31,** |
| | **2026** | **2026** | **2026** | **2025** | **2025** | **2025** |
| | **Pre-tax amount** | **Tax expense (benefit)** | **After-tax amount** | **Pre-tax amount** | **Tax expense (benefit)** | **After-tax amount** |
| | **(in millions)** | **(in millions)** | **(in millions)** | **(in millions)** | **(in millions)** | **(in millions)** |
| **Reconciliation of net income (loss) from continuing operations to Adjusted Net Income** <sup>(1)(2)</sup> |  |  |  |  |  |  |
| Net income (loss) from continuing operations | $9.3 | $3.6 | $5.7 | $(10.4) | $(2.3) | $(8.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt modification and extinguishment costs |  |  |  | 1.0 | 0.2 | 0.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss on asset disposals<sup>(a)</sup> | 0.4 | 0.1 | 0.3 | 0.2 | 0.1 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transaction and other related costs<sup>(b)</sup> | 1.2 | 0.3 | 0.9 | 0.8 | 0.2 | 0.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 3.4 | (0.5) | 3.9 | 2.5 | 0.3 | 2.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring, integration and business optimization expenses<sup>(c)</sup> | 0.8 | 0.2 | 0.6 | 0.1 |  | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other<sup>(d)</sup> | 1.0 | 0.2 | 0.8 | 0.5 | 0.1 | 0.4 |
| Adjusted Net Income | $16.1 | $3.9 | $12.2 | $(5.3) | $(1.4) | $(3.9) |

---

<sup>(1)</sup> We define Adjusted Net Income as net income (loss) from continuing operations adjusted for non-operating income or expense and the impact of certain non-cash or other items that are included in net income (loss) from continuing operations that we do not consider indicative of our ongoing operating performance. Adjusted Net Income is presented as a key performance indicator as we believe it will enhance a prospective investor's understanding of our results of operations and financial condition. Adjusted Net Income may not be comparable with net income (loss) from continuing operations or Adjusted Net Income as defined by other companies.

<sup>(2)</sup> Refer to the Adjusted EBITDA notes above for more information with respect to each adjustment.

The adjustments to net income (loss) from continuing operations are shown net of applicable tax rates of 25.4% and 25.0% for the three months ended March 31, 2026 and 2025, respectively, except for equity-based compensation. The tax effect on equity-based compensation is derived by removing the tax effect of any equity-based compensation expense disallowed as a result of its inclusion within Section 162(m) of the Internal Revenue Code of 1986 (as amended) and adjusting for the tax effect of the equity-based stock compensation net windfall or shortfall which is recorded as a discrete item.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**Financial Condition, Liquidity and Capital Resources**

Our primary sources of liquidity consist of cash flows from operations, existing cash balances as well as funds available under our asset based lending revolving credit facility ("ABL Facility"). We expect that ongoing requirements for debt service and capital expenditures will be funded from these sources of funds. Our primary liquidity requirements include funding working capital requirements (primarily inventory and accounts receivable, net of accounts payable and other accrued liabilities), debt service requirements and capital expenditures. Our capital expenditures include both maintenance of business, which include spending on maintenance and health, safety and environmental initiatives as well as growth, which includes spending to drive organic sales growth and cost savings initiatives.

We believe that our existing cash and cash equivalents and cash flows from operations, combined with availability under our ABL Facility, will be sufficient to meet our presently anticipated future cash needs for at least the next twelve months. We may also pursue strategic acquisition or divestiture opportunities, which may impact our future cash requirements. We may, from time to time, increase borrowings under our ABL Facility to meet our future cash needs. As of March 31, 2026, we had cash and cash equivalents of $162.6 million and availability of $74.3 million under our ABL Facility, after giving effect to $2.2 million of outstanding letters of credit, for a total available liquidity of $236.9 million. We did not have any revolving credit facility borrowings as of March 31, 2026. As of March 31, 2026, we were in compliance with all covenants under our debt agreements.

Our ABL Facility has one financial covenant with one ratio to maintain. The ratio compares the total ABL availability against a threshold: the greater of 10% of the line cap (which is defined as the lesser of our revolving loan commitments and the value of our assets) or $10.0 million. The greater of this threshold could not be greater than the total availability of the ABL Facility. As of March 31, 2026, we were in compliance with the financial covenant under the ABL Facility.

The 2025 Term Loan Facility and the ABL Facility contain various restrictive covenants. Each limits the ability of the Company and its restricted subsidiaries to incur certain indebtedness or liens, merge, consolidate or liquidate, dispose of certain property, make investments or declare or pay dividends, make optional payments, modify certain debt instruments, enter into certain transactions with affiliates, enter into certain sales and leasebacks and certain other non-financial restrictive covenants. During such time, the Company is required to maintain a fixed-charge coverage ratio of at least 1.0 to 1.0. The Company was in compliance with all debt covenants under the 2025 Term Loan Facility and the ABL Facility as of March 31, 2026.

We have no cash and cash equivalents held in foreign jurisdictions as of March 31, 2026.

Our liquidity requirements include interest payments related to our debt structure. As reported, our cash interest paid for the three months ended March 31, 2026 and 2025 was approximately $4.9 million and $12.3 million, respectively. Before any impact of hedges, a one percent change in assumed interest rates for our variable interest credit facilities would have an annual impact of approximately $4.0 million on interest expense.

We hedge the interest rate fluctuations on debt obligations through interest rate cap agreements. For more information about our interest rate cap agreements, refer to Note 12 — Financial Instruments of our condensed consolidated financial statements included in Part 1, Item 1 — Financial Statements (Unaudited).

***Off-Balance Sheet Arrangements***

The Company's off-balance sheet arrangements include $2.2 million of outstanding letters of credit on our ABL Facility as of March 31, 2026.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

***Cash Flow***

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| | **(in millions)** | **(in millions)** |
| *Continuing Operations* |  |  |
| Net cash provided by (used in): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating activities | $19.6 | $6.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing activities | (14.1) | (17.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing activities | (37.4) | (3.7) |
| *Discontinued Operations* |  |  |
| Net cash provided by (used in): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating activities | (2.7) | 3.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing activities |  | (7.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing activities |  | (0.8) |
| Net change in cash and cash equivalents | (34.6) | (18.5) |
| Cash and cash equivalents at beginning of period | 197.2 | 146.0 |
| Cash and cash equivalents at end of period | 162.6 | 127.5 |
| Less: cash, cash equivalents, and restricted cash of discontinued operations |  | (11.5) |
| Cash, cash equivalents and restricted cash at end of period of continuing operations | $162.6 | $116.0 |

---

The following discussions related to our cash flows are presented on a continuing operations basis, which excludes the cash flows from our Advanced Materials & Catalysts businesses accounted for as discontinued operations.

Net cash provided by operating activities was $19.6 million for the three months ended March 31, 2026, compared to $6.7 million for the three months ended March 31, 2025. Cash generated by operating activities, other than changes in working capital, was higher by $14.7 million during the three months ended March 31, 2026, as compared to the same period in the prior year primarily due to higher earnings exclusive of non-cash expenses. The decrease in cash from working capital during the three months ended March 31, 2026 of $1.6 million was unfavorable compared to the three months ended March 31, 2025 primarily due to unfavorable changes in receivables and inventories, partially offset by favorable changes in accounts payable and accrued liabilities.

The unfavorable change in inventory was primarily due to the effect of higher sulfur costs and timing of sales orders and inventory usage. The unfavorable change in receivables was driven by higher sulfur cost pass through and the timing of collection of sales. The favorable change in accounts payable was due to the timing of vendor payments. The favorable change in accrued liabilities mainly relates to the timing of payments for interest and other expenses.

Net cash used in investing activities was $14.1 million for the three months ended March 31, 2026, compared to $17.1 million during the same period in 2025. Net cash used in investing activities consisted of $14.1 million and $17.1 million to fund capital expenditures during the three months ended March 31, 2026 and 2025, respectively.

Net cash used in financing activities was $37.4 million for the three months ended March 31, 2026, compared to $3.7 million during the same period in 2025. The unfavorable change in net cash used in financing activities was primarily driven by higher repurchases of the Company's common stock during the three months ended March 31, 2026, partially offset by lower debt principal payments during the three months ended March 31, 2026

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

***Debt***

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| | **(in millions)** | **(in millions)** |
| 2025 Term Loan Facility | $397.1 | $397.1 |
| ABL Facility |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total debt | 397.1 | 397.1 |
| Original issue discount | (2.8) | (2.9) |
| Deferred financing costs | (1.5) | (1.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term debt, net of original issue discount and deferred financing costs | $392.8 | $392.6 |

---

As of March 31, 2026, our total debt was $397.1 million, excluding the original issue discount of $2.8 million and deferred financing costs of $1.5 million for our senior secured credit facilities. Our net debt as of March 31, 2026 was $234.5 million, which reflects our total debt of $397.1 million less cash and cash equivalents of $162.6 million. We may seek, subject to market conditions and other factors, opportunities to repurchase, refinance or otherwise reprice our debt.

***Capital Expenditures***

Maintenance capital expenditures include spending on maintenance of business, health, safety and environmental initiatives. Growth capital expenditures include spending to drive organic sales growth and cost savings initiatives. These capital expenditures represent our "book" capital expenditures for which the Company has recorded, but not necessarily paid for the capital expenditures.

---

| | | |
|:---|:---|:---|
| | **Three months ended<br>March 31,** | **Three months ended<br>March 31,** |
| | **2026** | **2025** |
| | **(in millions)** | **(in millions)** |
| Maintenance capital expenditures | $12.3 | $15.4 |
| Growth capital expenditures | 2.0 | 1.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total capital expenditures | $14.3 | $16.6 |

---

Capital expenditures remained at a level sufficient for required maintenance and certain expansion growth initiatives during these periods. Maintenance capital expenditures were lower in the three months ended March 31, 2026, compared to the three months ended March 31, 2025 due to timing of capital projects in 2025.

**Critical Accounting Policies and Estimates**

We prepare our condensed consolidated financial statements in conformity with GAAP and our significant accounting policies are described in Note 2 to our audited consolidated financial statements included in our Annual Report on Form 10-K. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect reported amounts and related disclosures. We base our estimates and judgments on historical experience and other relevant factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There has been no material change in our critical accounting policies and use of estimates from those described in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," included in our Annual Report on Form 10-K.

**Accounting Standards Not Yet Adopted**

See Note 2 to our unaudited condensed consolidated financial statements for a discussion of recently issued accounting standards and their effect on us.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ITEM 3.&nbsp;&nbsp;&nbsp;&nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.**

Our major market risk exposure is potential losses arising from changing rates and prices regarding interest rate risk and credit risk. The audit committee of our Board regularly reviews interest rate activity and monitors compliance with our hedging policy. We do not use financial instruments for speculative purposes, and we limit our hedging activity to the underlying economic exposure.

There have been no material changes in the interest rate risk or credit risk discussed in Item 7A., "Quantitative and Qualitative Disclosures about Market Risk," included in our Annual Report on Form 10-K.

**ITEM 4.&nbsp;&nbsp;&nbsp;&nbsp;CONTROLS AND PROCEDURES.**

***Evaluation of Disclosure Controls and Procedures***

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2026, the end of the period covered by this Quarterly Report on Form 10-Q.

The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended ("Exchange Act"), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable assurance level.

***Changes in Internal Control Over Financial Reporting***

No changes in our internal control over financial reporting occurred during the quarter ended March 31, 2026 that materially affected, or which are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**PART II**—**OTHER INFORMATION**

**ITEM 1.&nbsp;&nbsp;&nbsp;&nbsp;LEGAL PROCEEDINGS.**

From time to time, we may be subject to various legal claims and proceedings incidental to the normal conduct of business, relating to such matters as personal injury, product liability and warranty claims, waste disposal practices, release of chemicals into the environment and other matters that may arise in the ordinary course of our business. We currently believe that there is no litigation pending that is likely to have a material adverse effect on our business. Regardless of the outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

**ITEM 1A.&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS.**

"Item 1A, Risk Factors" in our Annual Report on Form 10-K includes a discussion of our risk factors. There have been no material changes from the risk factors described in our Annual Report on Form 10-K.

**ITEM 2.&nbsp;&nbsp;&nbsp;&nbsp;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.**

The following table contains information about purchases of our common stock, excluding excise tax, during the first quarter of 2026:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Total number of shares of common stock purchased**<sup>(1)</sup> | | **Average price paid per share of common stock**<sup>(2)</sup> | **Total number of shares of common stock purchased as part of publicly announced plan or programs** | **Maximum number (or dollar value) of shares of common stock that may yet be purchased under the plans or programs (in thousands)**<sup>(1)</sup> |
| January 1, 2026—January 31, 2026 | 1311875 | <sup>(3)</sup> | $10.58 | 1237739 | $169094 |
| February 1, 2026—February 28, 2026 | 1147922 | <sup>(3)</sup> | $11.29 | 1100450 | $156627 |
| March 1, 2026—March 31, 2026 | 888272 |  | $11.42 | 888272 | $146486 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | 3348069 |  |  |  |  |

---

<sup>(1)</sup> In April 2022, our Board approved and announced a new stock repurchase program authorizing the repurchase of up to $450 million of the Company's outstanding common stock over the next four years. In October 2025, the Board amended the Stock Repurchase Program to remove the limitation that all repurchases must be made within the four-year period from the date of original approval. This program is expected to be funded using cash on hand and cash generated from operations. For possible future repurchases, the actual timing, number, and nature of shares repurchased will depend on a variety of factors, including stock price, trading volume, and general business and market conditions and may be conducted through negotiated transactions, open market repurchases or other means, including through Rule 10b-18 and 10b5-1 trading plans or accelerated share repurchases. The repurchase program does not obligate us to acquire any number of shares in any specific period or at all and may be amended, suspended or discontinued at any time at our discretion.

During the three months ended March 31, 2026, the Company purchased 3,226,461 shares of its common stock on the open market pursuant to the stock repurchase program, for a total cost of $35.7 million. As of March 31, 2026, $146.5 million was available for share repurchases under the program.

<sup>(2)</sup> Excludes brokerage commissions and other costs of execution.

<sup>(3)</sup> Includes shares of common stock delivered to the Company by employees to satisfy income tax withholding obligations of the employees in connection with the vesting of restricted stock units.

**ITEM 5.&nbsp;&nbsp;&nbsp;&nbsp;OTHER INFORMATION.**

***Trading Arrangements***

During the three months ended March 31, 2026, none of the Company's directors or executive officers adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," each as defined in Item 408(a) of Regulation S-K.

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**ITEM 6.&nbsp;&nbsp;&nbsp;&nbsp;EXHIBITS.**

The following exhibits are being filed or furnished as part of this Quarterly Report on Form 10-Q:

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| 31.1 | <u>[Certification of Chief Executive Officer of Ecovyst Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex311-sec302ceocertx033120.htm)</u> |
| 31.2 | <u>[Certification of Chief Financial Officer of Ecovyst Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex312-sec302cfocertx033120.htm)</u> |
| 32.1 | <u>[Certification of Chief Executive Officer of Ecovyst Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex321-sec906ceocertx033120.htm)</u> |
| 32.2 | <u>[Certification of Chief Financial Officer of Ecovyst Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex322-sec906cfocertx033120.htm)</u> |
| 101 | The following materials from the Quarterly Report on Form 10-Q of Ecovyst Inc. for the quarter ended March 31, 2026, formatted in Inline XBRL: (i) Condensed Consolidated Statements of Income (Loss), (ii) Condensed Consolidated Statements of Comprehensive Income (Loss), (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statements of Stockholders' Equity, (v) Condensed Consolidated Statements of Cash Flows, (vi) Notes to Condensed Consolidated Financial Statements and (vii) document and entity information, tagged as blocks of text and including detailed tags |
| 104 | The cover page from the Quarterly Report on Form 10-Q of Ecovyst Inc. for the quarter ended March 31, 2026, formatted in Inline XBRL and included as Exhibit 101 |

---

------

<u>[**Table of Contents**](#i15573aa9b05948f0b3c16e51a49a9821_7)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | **Ecovyst Inc.** |
| &nbsp;&nbsp;Date: | May 5, 2026 | By: | /s/ MICHAEL FEEHAN |
|  |  |  | Michael Feehan |
|  |  |  | Vice President and Chief Financial Officer |
|  |  |  | (Duly Authorized Officer and Principal Financial and Accounting Officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER** 

**PURSUANT TO SECTION 302 OF THE**

**SARBANES-OXLEY ACT OF 2002**

I, Kurt J. Bitting, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Ecovyst Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | May 5, 2026 | /s/ KURT J. BITTING |
| | | Kurt J. Bitting |
| | | Chief Executive Officer |
| | | (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO SECTION 302 OF THE**

**SARBANES-OXLEY ACT OF 2002**

I, Michael Feehan, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Ecovyst Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | May 5, 2026 | /s/ MICHAEL FEEHAN |
| | | Michael Feehan |
| | | Vice President and Chief Financial Officer |
| | | (Principal Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of Ecovyst Inc. (the "Company") on Form 10-Q for the quarterly period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kurt J. Bitting, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: | May 5, 2026 | /s/ KURT J. BITTING |
| | | Kurt J. Bitting |
| | | Chief Executive Officer |
| | | (Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of Ecovyst Inc. (the "Company") on Form 10-Q for the quarterly period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Michael Feehan, Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: | May 5, 2026 | /s/ MICHAEL FEEHAN |
| | | Michael Feehan |
| | | Vice President and Chief Financial Officer |
| | | (Principal Financial Officer) |

---

<br>